Kornimate/medical-research-clean huggingface dataset:
follow-up care with or without cea assessments in patients who have undergone surgery for stage ii or stage iii colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: diagnostic procedures, such as ultrasound, x-ray, colonoscopy, ct scan, and cea assessment, may help monitor a patient's response to surgery. it is not yet known which follow-up regimen is more effective in patients who have undergone surgery for colorectal cancer. purpose: this randomized phase iii trial is comparing two types of follow-up care with or without cea assessments to see how well they work in patients who have undergone surgery for stage ii or stage iii colorectal cancer.

objectives: * evaluate the efficacy of reinforced versus standard follow-up care and the utility of follow-up cea assessments in patients with fully resected stage ii or iii colorectal cancer. outline: this is a multinational/multicenter study. patients are randomized to 1 of 2 follow-up arms. * standard follow-up: patients undergo clinical assessments every 3 months until year 3 and every 6 months until year 5. they are then assessed at least yearly thereafter. patients undergo abdominal ultrasound every 3 months until year 3 and then every 6 months until year 5; chest x-ray every 6 months until year 3 and then annually until year 5; and colonoscopy at 3 years after surgery then every 3 to 6 years thereafter. * reinforced follow-up: patients undergo clinical assessments every 3 months until year 3 and every 6 months until year 5. they are then assessed at least yearly thereafter. patients undergo alternate assessments every 3 months comprising thoraco-abdomino-pelvic ct scan or abdominal ultrasound until year 3 and then every 6 months until year 5. they also undergo colonoscopy at 3 years after surgery then every 3 to 6 years thereafter. patients undergo a second randomization to 1 of 2 follow-up arms at the beginning of the study. * cea measurement: patients undergo measurement of cea levels every 3 months until year 3, every 6 months until year 5, and at least yearly thereafter. * no cea measurement: patients do not undergo cea measurement. blood and tissue blocks of normal and tumor tissues are collected for the validation of protein serum, genetics, or immunologic markers predictive for relapse.

Eligibility criteria:
disease characteristics: * pathologically confirmed adenocarcinoma of the colon or rectum * stage ii or iii disease * no distant metastatic disease * has undergone curative resection for no residual tumor * carcinoembryonic antigen (cea) ≤ 1.5 x upper limit of normal after surgery patient characteristics: * who performance status 0-1 * not pregnant or nursing * fertile patients must use effective contraception * no inflammatory bowel disease * no other malignancy within the past 5 years except basal cell carcinoma of the skin and/or carcinoma in situ of the cervix * no genetic syndromes prior concurrent therapy: * see disease characteristics

Keywords: stage ii colon cancer stage ii rectal cancer stage iii colon cancer stage iii rectal cancer adenocarcinoma of the colon adenocarcinoma of the rectum
spirituality and will to live in patients with hiv/aids

Conditions: HIV Infections

Summary: this study is assessing the extent of spirituality in patients with hiv/aids and will determine the relationship between spirituality, health status, and the will to live.

approximately 1,000,000 americans have hiv/aids. although advances in treatment have made hiv/aids a relatively manageable chronic disease, the disease can cause significant morbidity and mortality. surprisingly, research has found that some hiv/aids patients feel that their life is better than it was before they had hiv/aids. many of these patients show a strong will to live and often express a preference for longevity over quality of life. patients who prefer longevity often ascribe their feeling to spiritual growth, or finding a meaning to life. this study is examining the spiritual beliefs of hiv/aids patients and will determine the relationship between spirituality, health status, and the will to live. the study consists of interviews with hiv/aids patients from cincinnati and washington, d.c. who have been interviewed twice over 12 to 18 months. during the interviews, participants completed self-report scales to assess their quality of life, life satisfaction, concerns about medication, trust in their health care providers, depressive symptoms, self-esteem, optimism, and various clinical and demographic variables. participants were also asked about their spiritual well-being; spiritual beliefs; spiritual, religious, and social support; and overall functioning.

Eligibility criteria:
inclusion criteria: * diagnosis of hiv or aids exclusion criteria: * none

Keywords: hiv aids spirituality
sers-based serum molecular spectral screening for lung cancer type

Conditions: Lung Cancer, Non-Small Cell; Lung Cancer Small Cell Lung Cancer (SCLC)

Summary: lung cancer can be divided into two major categories: small cell lung cancer (sclc) and non-small cell lung cancer (nsclc), with nsclc accounting for about 85% and sclc about 15%. the prognoses of different types of lung cancer vary significantly. early identification of different pathological types of lung cancer is crucial to the patient's prognosis. raman spectrum (rs), as a non-invasive and highly specific molecular detection technique, can obtain information at the molecular level, thereby sensitively detecting changes in biomolecules related to tumor metabolism such as proteins, nucleic acids, lipids, and sugars. surface-enhanced raman spectroscopy (sers), developed based on this technology, is one of the feasible methods for high-sensitivity biomolecular analysis. in preliminary study, the investigators collected serum raman spectral data from a cohort of 233 patients with malignant lung tumors and built a raman intelligent diagnostic system for sclc and nsclc based on a machine learning model, achieving an accuracy rate of 80%. to obtain the highest level of clinical evidence and truly achieve clinical translation, this prospective, multicenter clinical study aims to validate the use of this intelligent diagnostic system for the early diagnosis of sclc.

1. screening interested participants should sign the appropriate informed consent (icf) prior to completion any study procedures. 2. the investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. completion of baseline procedures, participants were assessed for 30 days and completed all safety monitoring. 4. after completing the baseline assessment and confirming enrollment, participants will be given 2ml of fasting venous blood.

Eligibility criteria:
inclusion criteria: 1. participants with lung cancer meeting the criteria of tnm (ninth edition); 2. participants are willing to participate in this study and follow the research plan; 3. participants or legally authorized representatives can give written informed consent approved by the ethics review committee that manages the website;. exclusion criteria: 1. participants with concomitant other malignant tumors; 2. participants with missing baseline clinical data; 3. participants with severe underlying pulmonary diseases (such as bronchiectasis, bronchial asthma, or copd), or those with a history of occupational or environmental exposure to dust, mines, or asbestos; 4. participants who are uncooperative or refuse to participate in the clinical trial later on.

Keywords: sers raman nsclc sclc diagnostic model
study of inborn errors of cholesterol synthesis and related disorders

Conditions: Lysosomal Storage Disease; Cholesterol Metabolism

Summary: this study will investigate the cause and medical problems associated with a group of genetic disorders known as inborn errors of cholesterol synthesis, in which the body does not produce cholesterol. people with this disorder may have birth defects and learning and behavioral problems. people with an inborn error of cholesterol synthesis and related disorders, including smith-lemli-opitz syndrome, lathosterolosis, desmosterolosis, x-linked dominant chondrodysplasia, child syndrome, greenberg dysplasia, and some cases of antley-bixler syndrome, may be eligible for this study. people who are carriers of the disorders also may enroll. participants and family members will provide blood and urine samples, as well as other tissue samples collected during medically indicated procedures such as biopsy or surgery. these tissues may include, for example, gallstones, cataracts, cerebrospinal fluid, amniotic fluid, lymph tissue, and dna samples. in rare instances, a skin biopsy may be requested to aid in establishing a diagnosis. medical information will also be gathered from medical records, photographs, and x-rays.

it is known that inborn errors of cholesterol synthesis give rise to human malformation/cognitive impairment syndromes. smith-lemli-opitz syndrome is the prototypical example of a post-squalene inborn error of metabolism; however, this group of disorders now includes lathosterolosis, desmosterolosis, x-linked dominant chondrodysplasia (cdpx2), child syndrome, hem dysplasia, and some cases of antley-bixler syndrome (1-3). due to the extremely rare occurrence of some of these disorders, the full phenotypic spectrum has yet to be defined. cholesterol transport in cells can also cause a disorder known as niemann-pick disease type c (npc). npc belongs to a group of disorders known as lysosomal storage disorders. the purpose of this protocol is to 1) allow for the collection of biomaterial and medical information that can be studied to gain insight into the pathological processes; 2) allow for the collection of dna and medical information from individuals who have a phenotypic resemblance to known disorders of cholesterol synthesis, lysosomal storage disorders or individuals who may be carriers of these disorders.

Eligibility criteria:
* inclusion criteria: subjects will be eligible for this study if they have or are suspected to have an inborn error of cholesterol synthesis or if they are related to a proband with a suspected inborn error of cholesterol synthesis. no exclusions will be made based on gender, ethnicity or age.

Keywords: inborn error of cholesterol synthesis cholesterol lysosomal storage natural history inborn errors of cholesterol synthesis smith-lemli-optiz syndrome lathosterolosis desmosterols child syndrome greenberg dysplasia x linked dominant chrondrodysplasia
cost (covid studio) action: study for the evaluation of specific antibodies anti covid-19 linked to covid-19 infection, symptoms and genetic expression of ace2 polymorphisms in patients (cost action)

Conditions: COVID-19

Summary: the aims of this study is to define the genetic bases of covid-19 related disease heterogeneity in frail population, to carry out a retrospective study on individuals w/wo symptoms to verify the reliability of a prognostic/diagnostic test based on igm/igg analysis and on the presence of genetic profiling and to explore the therapeutic potential of the modulation of ace2 expression.


Eligibility criteria:
inclusion criteria: * adult patients (\> 18 years old) exclusion criteria: * inability to understand and want; * mentally incapacitated.
use of rosuvastatin in hiv-infected subjects to modulate cardiovascular risks

Conditions: HIV Infections; Heart Disease

Summary: the hypothesis of this study is that 96 weeks of rosuvastatin will be safe and effective in decreasing cardiovascular risk and bone loss in the hiv+ population.

while the use of antiretroviral therapy (art) in recent years has had an impressive impact on mortality and disease progression in hiv-infected patients, nevertheless, cardiovascular disease is a major concern impacting morbidity and mortality in this population. this study will assess if a potent statin, rosuvastatin, could improve endothelial dysfunction, slow carotid intima media thickness (imt) progression and bone loss, and decrease inflammation and oxidative stress in hiv-infected art-treated subjects with good hiv virologic control. the investigators will also see if rosuvastatin will induce beneficial changes in the prevalence of metabolic syndrome and lipid metabolism as well as improve bone turnover markers.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hiv disease * age \> 18 years old * receiving a stable arv regimen for at least the last 12 weeks prior to study entry and cumulative duration of arv for 12 months * fasting ldl cholesterol \< 130 mg/dl * fasting triglycerides \< 300 mg/dl * hscrp \> 2 mg/l or cd38+dr+/cd8+ \> 19% * if on vit d replacement therapy, stable regimen for \> 3 months prior to study entry exclusion criteria: * women who are pregnant or breast feeding * any active or chronic inflammatory condition * cardiovascular disease * current or recent (within 24 weeks of study entry) therapy with omega-3 fatty acids, fibrates, ezetimibe or statins * uncontrolled hypothyroidism or hyperthyroidism * uncontrolled diabetes * use of systemic cancer chemotherapy of immunomodulating agents * use of anabolic agents, growth hormone, growth hormone releasing factor, or any other anabolic agents, except for stable replacement testosterone. * use of biphosphonates or other bone therapies * any of the following lab findings obtained within 14 days prior to the screening evaluation including the following: * ast and/or alt \> 2.5 x uln * hemoglobin \< 9.0 g/dl * ck \> 3 x uln * calculated creatinine clearance \< 50 ml/min

Keywords: hiv heart disease bone density
oral aripiprazole open-label rollover study

Conditions: Schizophrenia

Summary: the purpose of this study is to test the long-term safety and tolerability of oral aripiprazole in adolescent patients with schizophrenia.


Eligibility criteria:
inclusion criteria: * subjects with a confirmed axis i diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv) diagnosis of schizophrenia who must have completed otsuka study 31-03-241 (nct00102518) treatment of adolescent subjects with schizophrenia exclusion criteria: * patients with a co-morbid serious, uncontrolled systemic illness * patients with a significant risk of committing suicide

Keywords: open label aripiprazole
scale of therapeutic adherence to respiratory rahabilitation for lung cancer

Conditions: Lung Cancer

Summary: the goal of this non experimental, transversal instrument study is to construct and determine the reliability and validity of the scale of therapeutic adherence for respiratory rehabilitation in lung cancer in mexican patients with a lung cancer diagnosis. the main question it aims to answer is: what is the reliability and validity of the scale of therapeutic adherence for respiratory rehabilitation in lung cancer of the patients with this diagnosis that are currently undergoing an assessment or follow up program of respiratory rehabilitation? the scale of therapeutic adherence for respiratory rehabilitation in lung cancer (sta-rr-lc) will be psychometrically valid and reliable for the evaluation of therapeutic adherence on patients with lung cancer that are undergoing an assessment or follow up of respiratory rehabilitation.participants will be asked to fill out an identification card and fill out the fifty-six items presented on the sta-rr-lc.

for the recruitment patients with lung cancer diagnosis that arrive at the respiratory rehabilitation service will be asked if they are willing to participate and fill out the sta. it will be explained to them as clearly as possible the objective, procedure, risks and benefits of the study and a copy of the informed consent will be provided. lung cancer patients attending the pulmonary rehabilitation service will be approached and a verbal explanation of the study will be given.

Eligibility criteria:
inclusion criteria: * patients diagnosed with lung cancer (sclc and nsclc). * over 18 years of age. * voluntary participation by understanding and accepting the informed consent letter. * patients undergoing respiratory rehabilitation treatment with one month assessment and follow-up. * patients in active medical treatment. * any clinical stage. * karnofsky index ≥ 70. exclusion criteria: * severe hearing or visual problems that prevent them from understanding the instructions and answering the instruments (this will be identified as reported in the clinical record file). * severe psychiatric conditions (schizophrenia or psychotic disorders) and/or addiction to any psychoactive substance (this will be identified as reported in the incanet file). * attentional or memory problems that prevent them from understanding the instructions and answering the instruments (this will be identified as reported in the incanet file).

Keywords: pulmonary rehabilitation therapeutic adherence lung cancer
a study of lidocaine patch 5% alone, gabapentin alone, and lidocaine patch 5% and gabapentin in combination for the relief of pain in patients with diverse peripheral neuropathic pain conditions

Conditions: Postherpetic Neuralgia; Diabetic Neuropathy; Complex Regional Pain Syndrome; Carpal Tunnel Syndrome; HIV Neuropathy; Idiopathic Sensory Neuropathy; Peripheral Neuropathy

Summary: patients with postherpetic neuralgia (phn), diabetic neuropathy (dn), complex regional pain syndrome (crps), carpal tunnel syndrome, hiv neuropathy, idiopathic sensory neuropathy, or other peripheral neuropathy participated in a phase iv clinical trial to assess the comparative efficacy and safety of lidoderm monotherapy versus gabapentin monotherapy in treating a diverse group of peripheral neuropathic pain patients.


Eligibility criteria:
inclusion criteria: 1. had a diagnosis of phn, dn, crps, carpal tunnel syndrome, hiv neuropathy, idiopathic sensory neuropathy, or other peripheral neuropathy (upon mutual agreement of the sponsor and investigator) 2. patients with phn must have had pain \>3 months after rash healing 3. patients with dn must have had type i or ii diabetes and painful distal symmetric sensorimotor polyneuropathy with or without dynamic allodynia of the lower extremities 4. patients with crps must have met current iasp (international association for the study of pain) diagnostic criteria 5. patients with carpal tunnel syndrome must have had a diagnosis by combination clinical neurological examination (e.g., phalen's and tinel's signs), electrodiagnostic testing, and daily painful symptoms of at least 3 months' duration 6. patients with hiv neuropathy must have had hiv, subjective symptoms of painful peripheral neuropathy, and daily painful symptoms of at least 3 months' duration 7. patients with idiopathic sensory neuropathy must have had pain of at least 3 months' duration 8. reached an average daily pain rating during the baseline week of pain ratings greater than 4 on the 0-to-10 numerical pain rating scale (question 5 of the bpi) 9. had never received an analgesic regimen that contained lidocaine or gabapentin exclusion criteria: 1. had a neurological condition other than that associated with their pain diagnosis which, in the opinion of the investigator, would interfere with their ability to participate in the study 2. were taking a lidocaine-containing product that could not be discontinued while receiving lidocaine 3. were taking class 1 anti-arrhythmic drugs (e.g., mexiletine, tocainide)
the effectiveness of oral dexamethasone for acute bronchiolitis

Conditions: Bronchiolitis, Viral

Summary: this study will compare a single dose of oral dexamethasone to placebo in a multicenter, randomized, double blind trial of infants aged 2 to 12 months with first-time bronchiolitis (defined as wheezing within 7 days of onset). this is given as additional therapy beyond any other routine therapy used at that center. no current standard therapy is withheld, and no additional tests or other treatments are part of the study.the primary hypothesis is that dexamethasone will be more effective than placebo in preventing hospital admission. the secondary hypotheses are that dexamethasone will decrease respiratory scores and possibly the duration of the disease when compared to placebo, and that dexamethasone will be as safe and as well tolerated as placebo.

bronchiolitis is the most common lower respiratory infection in infants, and the respiratory condition leading to the most hospital admissions in young children. it is also probably the most common serious illness of childhood lacking evidence-based treatment. evidence both for and against the effectiveness of corticosteroids such as dexamethasone has been published. editorials, expert reviews, and a recent report from the agency for healthcare research and quality recommend a study such as this one. patients will be drawn from the emergency departments at participating medical centers in the pediatric emergency care applied research network, created by the emergency medical services for children program and the maternal and child health bureau of the health resources and services administration to study health problems of high acuity and high incidence in children. comparisons: the primary outcome (hospital admission after 4 hours of ed observation) and secondary outcomes will be compared between treatment and placebo groups.

Eligibility criteria:
inclusion criteria: * first attack of wheezing within 7 days of onset * age 2 months through 11 months (less than 12 months) * disease of at least moderate severity (rdai score greater than or equal to 6) exclusion criteria: * prior adverse reaction to dexamethasone * known heart or lung disease * premature birth prior to 36 weeks' gestation * history of prior asthma or bronchodilator use * immune suppression or deficiency * trisomy 21 * critical or life-threatening complications of bronchiolitis * treatment with corticosteroids within 14 days * known active chickenpox * exposure to chickenpox within 21 days * child sent to ed for automatic admission

Keywords: randomized clinical trial placebo-controlled double-blind double-masked infant dexamethasone wheezing